Ropes & Gray advised Profluent, an AI company pioneering large-scale foundation models for protein design, announced a multi-program strategic research collaboration with Eli Lilly and Company to develop and commercialize custom site-specific recombinases to address diseases with severe unmet needs. The deal was announced on April 28.
The collaboration focuses on enabling large-scale, precise DNA editing capabilities that remain out of reach using conventional gene editing systems. Under the agreement, Profluent will apply its AI models to design and optimize site-specific recombinases for multiple genomic targets. Lilly will receive an exclusive license to advance selected recombinases through in vivo research, preclinical development, clinical studies, and commercialization.
Profluent will receive an upfront payment in addition to committed research and development funding. In total, Profluent is eligible to receive up to $2.25 billion in development and commercial milestone payments plus tiered royalties on net sales.
The Ropes & Gray team included partner Brad Flint and associates Evan Tallmadge and James Gould.
Stay Up To Date with Ropes & Gray
Ropes & Gray attorneys provide timely analysis on legal developments, court decisions and changes in legislation and regulations.
Stay in the loop with all things Ropes & Gray, and find out more about our people, culture, initiatives and everything that’s happening.
We regularly notify our clients and contacts of significant legal developments, news, webinars and teleconferences that affect their industries.